Researchers at BACE meeting explore how trafficking and degradation of the protease relate to amyloid pathology in AD.
In neurodegenerative disease, tau is in the dendrites, and scientists are beginning to flesh out ways to block what it does there.
Researchers at a meeting on BACE shared concerns that blocking the protease in adults might have unexpected consequences.
G8 leaders set 2025 as their goal to find better treatment for Alzheimer's and vowed to coordinate research and care strategies.
A European public-private partnership plans to combine faster enrollment with adaptive trials to hasten drug discovery in Alzheimer's.
As new substrates and functions for BACE continue to emerge, scientists worry about adverse effects of blocking the protease.
Once branded as a difficult target, β-secretase has become the crowd favorite. But might pharma have to cool its jets?
Scientists are tweaking immune pathways to scavenge amyloid and curb symptoms in Alzheimer’s mice.
New research reveals fundamental roles for astrocytes and microglia in shaping neural circuits.
A gene therapy approach to protect cholinergic neurons appeared safe and seemed to stabilize brain metabolism in a Phase 1 trial of AD patients.
The Internet is poised to play a growing role in recruiting for Alzheimer’s clinical trials.
In the early days of tau brain imaging, neurofibrillary pathology appears to match up with the subtle cognitive decline of presymptomatic Alzheimer’s.
New strategies may help find and retain participants for Alzheimer’s trials.
With several microRNAs being overly active in ALS, an antisense therapy to one slows the disease in mice, apparently by reducing neuroinflammation.
Researchers propose four stages of TDP-43 pathology based on the spread of the protein through the brain.